Stock exchange releases

Stock exchange releases

Go to press releases

07.05.2010 Biotie Therapies interim report: January - March 2010
26.04.2010 Biotie reports positive top-line data from clinical study with its third generation oral PDE4 inhibitor - ELB353 is well tolerated and shows clear pharmacological activity
22.04.2010 Biotie to continue development of and maintain global rights to BTT-1023, its novel VAP-1 antibody for inflammatory disease
15.04.2010 Resolutions of the Annual General Meeting of Biotie Therapies Corp.
07.04.2010 Revised proposal from the Board's Nomination and Remuneration Committee to the Annual General Meeting of shareholders
17.03.2010 Invitation to The Annual General Meeting of Biotie Therapies Corp.
15.03.2010 Biotie's Stock Exchange Releases published in 2009
15.03.2010 Biotie's Annual Report 2009 and Corporate Governance Statement have been published
10.03.2010 Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act relating to decrease in holdings
09.03.2010 Biotie Provides Update on Pfizer Research Collaboration
26.02.2010 Biotie Therapies Corp. financial statement release January 1 - December 31, 2009
23.02.2010 Biotie will publish its Financial Statement Release for 1 January - 31 December 2009 on Friday, 26 February 2010 at 9.00 a.m. Finnish time
19.01.2010 Biotie reports positive top-line data from clinical study with VAP-1 antibody in rheumatoid arthritis patients - BTT-1023 is well tolerated and shows signals of therapeutic activity
13.01.2010 Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act relating to decrease in holdings